The influence of Trisenox on actin organization in HL-60 cells

Central European Journal of Biology

Volumn 4, Issue 3, 2009, Pages 351-361

  Izdebska, Magdalena ^a   Grzanka, Dariusz ^a   Gackowska, Lidia ^a   Zuryń, Agnieszka ^a   Grzanka, Alina ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Apoptosis; F actin; Flow cytometry; Fluorescence; HL 60; Trisenox (arsenic trioxide, ATO)

Indexed keywords

EID: 70350047066     PISSN: 1895104X     EISSN: 16443632     Source Type: Journal    
DOI: 10.2478/s11535-009-0021-5     Document Type: Article

References (51)

1. Zhu J., Okumura H., Ohtake S., Nakamura S., Nakao S., Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system, Oncol. Rep., 2003, 10, 705-770.
2. Waxman S., Anderson K.C., History of the development of arsenic derivatives in cancer therapy, Oncologist, 2001, 6, 3-10.
3. 4 cells apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins, Blood, 1996, 88, 1052-1061.
4. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., et al., Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, N. Engl. J. Med., 1998, 339, 1341-1348.
5. Tarkanyi I., Dudognon C., Hillion J., Pendino F., Lanotte M., Aradi J., et al., Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death, Leukemia, 2005, 19, 1806-1811.
6. Germolec D.R., Spalding J., Yu H.S., Chen G.S., Simeonova P.P., Humble M.C., et al., Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors, Am. J. Pathol., 1998, 153, 1775-1785.
7. Grad J.M., Bahlis N.J., Reis I., Oshiro M.M., Dalton W.S., Boise L.H., Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells, Blood, 2001, 98, 805-813.
8. Liu Q., Hilsenbeck S., Gazitt Y., Arsenic trioxideinduced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL, Blood, 2003, 101, 4078-4087.
9. Shao Q.S., Ye Z.Y., Ling Z.Q., Ke J.J., Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide, World J. Gastroenterol., 2005, 11, 3451-3456.
10. Ishitsuka K., Ikeda R., Utsunomiya A., Uozumi K., Hanada S., Suzuki S., et al., Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation, Leuk. Lymphoma, 2002, 43, 1107-1114.
11. 3) on human breast cancer cells, J. Cell Biochem., 2004, 93, 173-187.
12. Kanzawa T., Zhang L., Xiao L., Germano I.M., Kondo Y., Kondo S., Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3, Oncogene, 2005, 24, 980-991.
13. Uslu R., Sanli U.A., Sezgin C., Karabulut B., Terzioglu E., Omay S.B., et al., Arsenic trioxidemediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines, Clin. Cancer Res., 2000, 6, 4957-4964.
14. Bornstein J., Sagi S., Haj A., Harroch J., Fares F., Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line, Gynecol. Oncol., 2005, 99, 726-729.
15. Davison K., Mann K.K., Waxman S., Miller W.H. Jr, JNK activation is a mediator of arsenic trioxideinduced apoptosis in acute promyelocytic leukemia cells, Blood, 2004, 103, 3496-3502.
16. Kitamura K., Minami Y., Yamamoto K., Akao Y., Kiyoi H., Saito H., et al., Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis, Leukemia, 2000, 14, 1743-1750.
17. Mathas S., Lietz A., Janz M., Hinz M., Jundt F., Scheidereit C., et al., Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis, Blood, 2003, 102, 1028-1034.
18. Miller W.H. Jr, Schipper H.M., Lee J.S., Singer J., Waxman S., Mechanisms of action of arsenic trioxide, Cancer Res., 2002, 62, 3893-3903.
19. Muscarella D.E., Bloom S.E., Differential activation of the c-Jun N-terminal kinase pathway in arseniteinduced apoptosis and sensitization of chemically resistant compared to susceptible B-lymphoma cell lines, Toxicol. Sci., 2002, 68, 82-92.
20. Abercrombie M., The crawling movement of metazoan cells, Proc. R. Soc. Lond. B. Biol. Sci., 1980, 207, 129-147.
21. Carlier M.F., Ressad F., Pantaloni D., Control of actin dynamics in cell motility. Role of ADF/cofilin, J. Biol. Chem., 1999, 274, 33827-33830.
22. Grzanka A., Dykiert P., Izdebska M., Grzanka D., The involvement of F-actin in apoptotic body formation in CHOAA8 cells treated with doxorubicin, Med. Biol. Sci., 2005, 19, 49-54.
23. Rando O.J., Zhao K., Crabtree G.R., Searching for a function for nuclear actin, Trends Cell Biol., 2000, 10, 92-97.
24. Pederson T., As functional nuclear actin comes into view, is it globular, filamentous, or both?, J. Cell Biol., 2008, 17, 1061-1064.
25. Sauman I., Berry S.J., An actin infrastructure is associated with eukaryotic chromosomes: structural and functional significance, Eur. J. Cell Biol., 1994, 64, 348-356.
26. Nishida E., Iida K., Yonezawa N., Koyasu S., Yahara I., Sakai H., Cofilin is a component of intranuclear and cytoplasmic actin rods induced in cultured cells, Proc. Natl. Acad. Sci. USA, 1987, 84, 5262-5266.
27. Shestakova E.A., Motuz L.P., Minin A.A., Gavrilova L.P., Study of localization of the protein-synthesizing machinery along actin filament bundles, Cell Biol., Int., 1993, 17, 409-416.
28. Milankov K., De Boni U., Cytochemical localization of actin and myosin aggregates in interphase nuclei in situ, Exp. Cell Res., 1993, 209, 189-199.
29. Soyer-Gobillard M.O., Ausseil J., Géraud M.L., Nuclear and cytoplasmic actin in dinoflagellates, Biol. Cell, 1996, 87, 17-35.
30. Funaki K., Katsumoto T., Iino A., Immunocytochemical localization of actin in the nucleolus of rat oocytes, Biol. Cell, 1995, 84, 139-146.
31. Zhao K., Wang W., Rando O.J., Xue Y., Swiderek K., Kuo A., et al., Rapid and phosphoinositoldependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling, Cell, 1998, 95, 625-636.
32. Percipalle P., Zhao J., Pope B., Weeds A., Lindberg U., Daneholt B., Actin bound to the heterogeneous nuclear ribonucleoprotein hrp36 is associated with Balbiani ring mRNA from the gene to polysomes, J. Cell Biol., 2001, 153, 229-236.
33. Sahlas D.J., Milankov K., Park P.C., De Boni U., Distribution of snRNPs, splicing factor SC-35 and actin in interphase nuclei: immunocytochemical evidence for differential distribution during changes in functional states, J. Cell Sci., 1993, 105, 347-357.
34. Hayashi T., Hideshima T., Akiyama M., Richardson P., Schlossman R.L., Chauhan D., et al., Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment, Mol. Cancer Ther., 2002, 1, 851-860.
35. Kerbauy D.M., Lesnikov V., Abbasi N., Seal S., Scott B., Deeg H.J., NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs), Blood, 2005, 106, 3917-3925.
36. Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., et al., The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms, Leukemia, 1998, 12, 1383-1391.
37. Shen Z.Y., Xu L.Y., Li E.M., Li J.T., Chen M.H., Shen J., et al., Ezrin, actin and cytoskeleton in apoptosis of esophageal epithelial cells induced by arsenic trioxide, Int. J. Mol. Med., 2003, 12, 341-347.
38. Grzanka A., Grzanka D., Orlikowska M., Cytoskeletal reorganization during process of apoptosis induced by cytostatic drugs in K-562 and HL-60 leukemia cell lines, Biochem. Pharmacol., 2003, 66, 1611-1617.
39. Veselska R., Zitterbart K., Jelinkova S., Neradil J., Svoboda A., Specific cytoskeleton changes during apoptosis accompanying induced differentiation of HL-60 myeloid leukemia cells, Oncol. Rep., 2003, 10, 1049-1058.
40. Olins A.L., Herrmann H., Lichter P., Olins D.E., Retinoic acid differentiation of HL-60 cells promotes cytoskeletal polarization, Exp. Cell Res., 2000, 254, 130-142.
41. Grzanka A., Grzanka D., Orlikowska M., Fluorescence and ultrastructural localization of actin distribution patterns in the nucleus of HL-60 and K-562 cell lines treated with cytostatic drugs, Oncol. Rep., 2004, 11, 765-770.
42. Pederson T., Aebi U., Actin in the nucleus: what form and what for?, J. Struct. Biol., 2002, 140, 3-9.
43. Pederson T., Aebi U., Nuclear actin extends, with no contraction in sight, Mol. Biol. Cell, 2005, 16, 5055-5060.
44. Olave I.A., Reck-Peterson S., Crabtree G.R., Nuclear actin and actin-related proteins in chromatin remodeling, Annu. Rev. Biochem., 2002, 71, 755-781.
45. Widlak P., Palyvoda O., Kumala S., Garrard W.T., Modeling apoptotic chromatin condensation in normal cell nuclei, J. Biol. Chem., 2002, 277, 21683-21690.
46. McDonald D., Carrero G., Andrin C., de Vries G., Hendzel M.J., Nucleoplasmic beta-actin exists in a dynamic equilibrium between low-mobility polymeric species and rapidly diffusing populations, J. Cell Biol., 2006, 172, 541-552.
47. Starr D., Han M., Role of ANC-1 in tethering nuclei to the actin cytoskeleton, Science, 2002, 298, 406-409.
48. Hofmann W., Reichart B., Ewald A., Muller E., Schmitt I., Stauber R.H., et al., Cofactor requirements for nuclear export of Rev response element (RRE)- and constitutive transport element (CTE)-containing retroviral RNAs. An unexpected role for actin, J. Cell Biol., 2001, 152, 895-910.
49. Wasser M., Chia W., The EAST protein of drosophila controls an expandable nuclear endoskeleton, Nat. Cell Biol., 2000, 2, 268-275.
50. Park J.W., Choi Y.J., Jang M.A., Baek S.H., Lim J.H., Passaniti T., et al., Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl- phosphorylation in promonocytic U937 cells, Biochem. Biophys. Res. Commun., 2001, 286, 726-734.
51. Ishitsuka K., Hanada S., Uozumi K., Utsunomiya A., Arima T., Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines, Leuk. Lymphoma, 2000, 37, 649-655.